0001209191-23-043998.txt : 20230801 0001209191-23-043998.hdr.sgml : 20230801 20230801163649 ACCESSION NUMBER: 0001209191-23-043998 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230728 FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: King Simona CENTRAL INDEX KEY: 0001879312 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39231 FILM NUMBER: 231132315 MAIL ADDRESS: STREET 1: C/O PASSAGE BIO, INC. STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Passage BIO, Inc. CENTRAL INDEX KEY: 0001787297 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822729751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 2678660312 MAIL ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-28 0 0001787297 Passage BIO, Inc. PASG 0001879312 King Simona ONE COMMERCE SQUARE 2005 MARKET STREET, 39TH FLOOR PHILADELPHIA PA 19103 0 1 0 0 Chief Financial Officer 0 Common Stock 2023-07-28 4 M 0 31250 0.00 A 35447 D Common Stock 2023-07-28 4 S 0 11453 0.88 D 23994 D Restricted Stock Units 2023-07-28 4 M 0 31250 0.00 D Common Stock 31250 0 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer. /s/ Edgar Cale, Attorney-in-Fact 2023-08-01